Your browser is no longer supported. Please, upgrade your browser.
Settings
PTLA Portola Pharmaceuticals, Inc. daily Stock Chart
PTLA [NASD]
Portola Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-5.38 Insider Own1.40% Shs Outstand66.17M Perf Week8.48%
Market Cap2.05B Forward P/E- EPS next Y-3.83 Insider Trans54.25% Shs Float65.63M Perf Month21.27%
Income-353.50M PEG- EPS next Q-1.11 Inst Own- Short Float28.18% Perf Quarter54.18%
Sales34.60M P/S59.20 EPS this Y-0.90% Inst Trans7.83% Short Ratio10.62 Perf Half Y23.00%
Book/sh2.49 P/B12.43 EPS next Y24.20% ROA-69.70% Target Price36.17 Perf Year-34.49%
Cash/sh5.59 P/C5.54 EPS next 5Y- ROE-136.30% 52W Range14.81 - 50.20 Perf YTD58.61%
Dividend- P/FCF- EPS past 5Y- ROI-60.40% 52W High-38.33% Beta2.36
Dividend %- Quick Ratio6.50 Sales past 5Y-20.70% Gross Margin82.80% 52W Low109.05% ATR1.14
Employees252 Current Ratio6.60 Sales Q/Q273.70% Oper. Margin- RSI (14)77.65 Volatility3.21% 4.19%
OptionableYes Debt/Eq1.28 EPS Q/Q23.40% Profit Margin- Rel Volume0.67 Prev Close29.81
ShortableYes LT Debt/Eq1.23 EarningsMar 01 BMO Payout- Avg Volume1.74M Price30.96
Recom- SMA2013.35% SMA5035.19% SMA2004.99% Volume1,164,235 Change3.86%
Aug-27-18Upgrade Credit Suisse Underperform → Neutral
Aug-10-18Downgrade Credit Suisse Neutral → Underperform
Mar-01-18Downgrade Morgan Stanley Overweight → Equal-Weight
Dec-01-17Initiated Goldman Buy $75
Aug-24-17Upgrade Credit Suisse Neutral → Outperform
Jun-26-17Reiterated Morgan Stanley Overweight $50 → $70
Jun-26-17Reiterated Citigroup Buy $51 → $78
Feb-24-17Upgrade Oppenheimer Perform → Outperform
Jan-03-17Upgrade Citigroup Neutral → Buy
Dec-27-16Reiterated Credit Suisse Outperform $20 → $29
Aug-19-16Downgrade Citigroup Buy → Neutral
May-31-16Downgrade Credit Suisse Outperform → Neutral $33 → $30
Mar-28-16Reiterated Credit Suisse Outperform $47 → $34
Mar-28-16Downgrade Goldman Buy → Neutral $65 → $30
Dec-18-15Initiated Goldman Buy
Feb-07-19 04:03PM  Portola Pharmaceuticals Announces Full Results from the ANNEXA-4 Study of the Factor Xa Inhibitor Reversal Agent Andexxa® in Patients with Life-Threatening Bleeding GlobeNewswire
Feb-01-19 11:45AM  Is There An Opportunity With Portola Pharmaceuticals, Inc.s (NASDAQ:PTLA) 22.17% Undervaluation? Simply Wall St.
08:30AM  Portola Pharmaceuticals to Announce Fourth Quarter and Full Year 2018 Financial Results on Friday, March 1, 2019 GlobeNewswire
Jan-30-19 08:43AM  Portola Pharmaceuticals to Present Full Results from the ANNEXA-4 Study of Andexxa During a Late-Breaking Oral Presentation at the International Stroke Conference 2019 GlobeNewswire
Jan-28-19 09:23AM  Portola Pharmaceuticals Appoints Sheldon Koenig as Chief Commercial Officer GlobeNewswire
Jan-03-19 02:01PM  Take Profits on This Pharma Stock Schaeffer's Investment Research
Jan-02-19 09:25AM  Portola Up as Large-Scale Andexxa Production Gets FDA Nod Zacks
Dec-31-18 03:59PM  Portola stock shoots higher after FDA approval MarketWatch +14.22%
03:19PM  U.S. Food and Drug Administration Approves Portola Pharmaceuticals Prior Approval Supplement for Andexxa® Generation 2 Manufacturing Process GlobeNewswire
Dec-18-18 08:30AM  Portola Pharmaceuticals to Webcast Corporate Update on January 8, 2019 GlobeNewswire
Dec-17-18 02:58PM  Portola Pharmaceuticals, Inc. (NASDAQ:PTLA): Is Breakeven Near? Simply Wall St.
Dec-13-18 04:45PM  Here's Why Portola Pharmaceuticals Fell 11% Today Motley Fool -11.40%
12:07AM  Is Portola Pharmaceuticals Inc (PTLA) A Good Stock To Buy? Insider Monkey
Dec-12-18 10:15AM  Portola (PTLA) Down as CHMP Defers Review Date for Ondexxya Zacks +10.62%
Dec-11-18 11:13AM  Portola Pharma shares slide 6% on news of delay in EU review of treatment for bleeding MarketWatch -6.65%
07:00AM  CHMP Extends Review Period for Portola Pharmaceuticals Ondexxya (andexanet alfa) GlobeNewswire
Dec-04-18 07:30AM  Recent Analysis Shows Portola Pharmaceuticals, Xenia Hotels & Resorts, WestRock, Newtek Business Services, The ExOne, and VMware Market Influences Renewed Outlook, Key Drivers of Growth GlobeNewswire -5.71%
Dec-03-18 09:15PM  Updated Interim Results from Ongoing Phase 2a Study of Portola Pharmaceuticals Oral Syk/JAK Inhibitor Cerdulatinib Continues to Demonstrate Clinical Responses in Heavily Pre-Treated T-Cell Malignancies GlobeNewswire
Nov-09-18 09:16AM  Here's What Portola Pharmaceuticals Is Saying About Its Future Motley Fool -5.14%
Nov-08-18 07:05AM  Today's Research Reports on Trending Tickers: Portola Pharmaceuticals and Global Blood Therapeutics ACCESSWIRE +21.41%
Nov-07-18 11:31PM  Edited Transcript of PTLA earnings conference call or presentation 7-Nov-18 9:30pm GMT Thomson Reuters StreetEvents
07:30PM  Portola Pharmaceuticals (PTLA) Reports Q3 Loss, Tops Revenue Estimates Zacks
06:26PM  Portola Pharmaceuticals: 3Q Earnings Snapshot Associated Press
04:05PM  Portola Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Corporate Update GlobeNewswire
Nov-06-18 04:30PM  Portola Pharmaceuticals to Participate in Two Upcoming Investor Conferences GlobeNewswire -5.12%
Nov-01-18 05:30PM  Portola Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire +5.64%
04:03PM  Portola Pharmaceuticals to Present New Interim Phase 2 Results for Cerdulatinib During an Oral Session at the 60th American Society of Hematology (ASH) Annual Meeting GlobeNewswire
Oct-25-18 08:25AM  Factors of Influence in 2018, Key Indicators and Opportunity within Portola Pharmaceuticals, Cable One, Marriot Vacations Worldwide, United Technologies, Park-Ohio, and BioScrip New Research Emphasizes Economic Growth GlobeNewswire
Oct-23-18 08:30AM  Portola Pharmaceuticals to Announce Third Quarter 2018 Financial Results and Host Conference Call on Wednesday, November 7, 2018 GlobeNewswire
Oct-11-18 03:36PM  Why Portola Pharmaceuticals Stock Shed 11% in September Motley Fool
Oct-09-18 03:44PM  What You Must Know About Portola Pharmaceuticals Incs (NASDAQ:PTLA) Market Risks Simply Wall St.
09:05AM  Portola Pharmaceuticals Supports 2018 World Thrombosis Day Campaign to Raise Awareness of Blood Clots as an Urgent and Growing Health Crisis GlobeNewswire
Sep-26-18 11:14AM  Portola's (PTLA) Lymphoma Candidate Gets Orphan Drug Status Zacks
Sep-25-18 04:38PM  Portola Pharmaceuticals Receives FDA Orphan Drug Designation for Cerdulatinib, an Oral Syk/JAK Inhibitor for the Treatment of Peripheral T-Cell Lymphoma GlobeNewswire
Sep-24-18 11:10AM  Health Care Digest: Genentech's neuro legacy, uBiome's haul, plus saving moms American City Business Journals
Sep-20-18 08:30AM  Portola Pharmaceuticals Names Scott Garland President and Chief Executive Officer GlobeNewswire
Sep-12-18 08:26AM  The Daily Biotech Pulse: Foamix Jumps on Data, Positive Results for Galapagos-Gilead's Rheumatoid Arthritis Drug, Bausch Health Trims Debt Benzinga
Sep-11-18 06:06PM  U.S. FDA Assigns PDUFA Date to Portola Pharmaceuticals Prior Approval Supplement for the Large-Scale Generation 2 Andexxa Process GlobeNewswire
02:07PM  Here's Why Portola Pharmaceuticals, Inc. Fell 16.6% in August Motley Fool
Sep-07-18 08:30AM  Portola Pharmaceuticals Announces Executive Leadership Change GlobeNewswire
08:18AM  3 Top Biotech Stocks to Buy in September Motley Fool
Sep-05-18 06:15PM  Portola Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire
08:30AM  Market Trends Toward New Normal in Shutterstock, CrossAmerica Partners LP, Allegiance Bancshares, Portola Pharmaceuticals, StoneMor Partners, and Catalyst Biosciences Emerging Consolidated Expectations, Analyst Ratings GlobeNewswire
Aug-31-18 08:30AM  Portola Pharmaceuticals Submits Prior Approval Supplement to U.S. FDA for Large-Scale Generation 2 Andexxa Process GlobeNewswire +5.51%
Aug-30-18 08:00AM  Portola Pharmaceuticals to Participate in Two Upcoming Investor Conferences GlobeNewswire
Aug-29-18 07:30AM  [$$] Portola Pharmaceuticals Director Scores With Stock Purchase Barrons.com
Aug-27-18 10:31AM  Sympathy Move: Portola Upgraded After Competitor Reports Sour Data Benzinga
09:56AM  Portola Pharmaceuticals (PTLA) Jumps: Stock Rises 9.1% Zacks
08:00AM  Today's Research Reports on Trending Tickers: Portola Pharmaceuticals and AVEO Pharmaceuticals ACCESSWIRE
Aug-25-18 06:01PM  Insider Buys Of The Week: Andeavor, Corcept, Portola Benzinga
Aug-16-18 08:25AM  Factors of Influence in 2018, Key Indicators and Opportunity within BioScrip, Powell Industries, Portola Pharmaceuticals, Daktronics, Cable One, and Park-Ohio New Research Emphasizes Economic Growth GlobeNewswire
Aug-10-18 05:45PM  Edited Transcript of PTLA earnings conference call or presentation 9-Aug-18 12:30pm GMT Thomson Reuters StreetEvents -5.39%
08:00AM  Todays Research Reports on Stocks to Watch: Portola Pharmaceuticals and Idera Pharmaceuticals ACCESSWIRE
Aug-09-18 05:08PM  Why Portola Pharmaceuticals Tumbled 18.3% Today Motley Fool -18.32%
09:20AM  Portola Pharmaceuticals (PTLA) Reports Q2 Loss, Lags Revenue Estimates Zacks
08:13AM  Portola Pharmaceuticals: 2Q Earnings Snapshot Associated Press
08:01AM  Portola Pharmaceuticals Reports Second Quarter 2018 Financial Results and Provides Corporate Update GlobeNewswire
08:00AM  Portola Pharmaceuticals Appoints Ernie Meyer as Executive Vice President and Chief Human Resources Officer GlobeNewswire
06:30AM  Portola Pharmaceuticals, Inc. to Host Earnings Call ACCESSWIRE
Aug-08-18 10:18AM  Portola Pharma's Q2 Earnings Outlook Benzinga
Aug-06-18 08:00AM  Today's Research Reports on Trending Tickers: Portola Pharmaceuticals and United Therapeutics ACCESSWIRE
Aug-03-18 08:00AM  U.S. Centers for Medicare and Medicaid Services (CMS) Grants New Technology Add-On Payment for Portola Pharmaceuticals Andexxa GlobeNewswire
Aug-02-18 08:30AM  Portola Pharmaceuticals to Announce Second Quarter 2018 Financial Results and Host Conference Call on Thursday, August 9, 2018 GlobeNewswire
Jul-27-18 08:24AM  European CHMP Maintains Negative Opinion on Portola Pharmaceuticals Betrixaban Following Appeal GlobeNewswire -7.51%
Jul-24-18 08:10AM  Today's Research Reports on Trending Tickers: Portola Pharmaceuticals and Tenet Healthcare ACCESSWIRE
Jul-19-18 07:05AM  Free Technical Reports on Portola Pharma and Three Additional Biotech Equities ACCESSWIRE
Jul-03-18 08:30AM  Portola Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire
Jun-26-18 10:12AM  Portola Pharmaceuticals Inc (NASDAQ:PTLA): Are Analysts Optimistic? Simply Wall St.
Jun-25-18 08:30AM  Portola Pharmaceuticals Appoints 30-Year Industry Veteran Glenn Brame as Senior Vice President of Technical Operations GlobeNewswire
Jun-19-18 08:00AM  Today's Research Reports on Trending Tickers: Portola Pharmaceuticals and Biogen ACCESSWIRE
Jun-05-18 09:31PM  Is an Acquisition in Portola Pharmaceuticals' Future? Motley Fool
04:30PM  Portola Pharmaceuticals to Present at Two Upcoming Investor Conferences GlobeNewswire
08:05AM  Benzinga's Daily Biotech Pulse: Mylan's Neulasta Biosimilar Approved, Portola's CEO To Retire, Regenxbio To Join S&P SmallCap Index Benzinga
Jun-04-18 04:30PM  Portola Pharmaceuticals Announces Retirement of CEO Bill Lis in 2018 GlobeNewswire
04:14PM  After-hours buzz: SBUX, TWTR & more CNBC
08:30AM  New Interim Phase 2a Study Results Demonstrate Broad Clinical Activity of Portola Pharmaceuticals Oral SYK/JAK Inhibitor Cerdulatinib GlobeNewswire
May-24-18 08:30AM  Portola Pharmaceuticals Receives $100 Million Milestone Payment from HealthCare Royalty Partners for FDA Approval of Andexxa® GlobeNewswire
May-14-18 06:36PM  Portola Takes Another Big Step Forward Motley Fool
05:37PM  Will athenahealth Be the Next Big Healthcare Deal? Motley Fool
May-10-18 01:46PM  Edited Transcript of PTLA earnings conference call or presentation 9-May-18 8:30pm GMT Thomson Reuters StreetEvents
May-09-18 07:26PM  Portola Pharmaceuticals: 1Q Earnings Snapshot Associated Press
04:05PM  Portola Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Corporate Update GlobeNewswire
May-08-18 08:51PM  Is There An Opportunity With Portola Pharmaceuticals Incs (NASDAQ:PTLA) 33% Undervaluation? Simply Wall St.
07:00AM  Blog Exposure - Portola Pharma Receives Approval from FDA for Its Lead Candidate ACCESSWIRE
May-07-18 08:10AM  Todays Research Reports on Stocks to Watch: ACADIA Pharmaceuticals and Portola Pharmaceuticals ACCESSWIRE
May-05-18 08:31AM  This Biotech Stock Could Be Like Buying Celgene in 2006 Motley Fool
07:17AM  3 Healthcare Stocks That Soared This Week: Are They Buys? Motley Fool
May-04-18 05:35PM  As emergency blood-thinner antidote scores FDA OK, Peninsula drug maker's stock soars American City Business Journals +25.64%
04:41PM  Why Portola Pharmaceuticals Skyrocketed 25.6% Today Motley Fool
02:14PM  Portola Pharma Rips 20% Higher After FDA Approves Andexxa Antidote Benzinga
11:54AM  Rally on! Heres Why Portola Pharmaceuticals (PTLA) Shares Jumped 20% Today SmarterAnalyst
09:27AM  Benzinga Pro's 5 Stocks To Watch Today Benzinga
08:16AM  Benzinga's Daily Biotech Pulse: Portola Receives FDA Nod, Mallinckrodt Gets Thumbs Down Benzinga
May-03-18 09:49PM  U.S. FDA Approves Portola Pharmaceuticals Andexxa®, First and Only Antidote for the Reversal of Factor Xa Inhibitors GlobeNewswire
May-02-18 07:50AM  Factors of Influence in 2018, Key Indicators and Opportunity within Independent Bank Group, Eclipse Resources, Stellus Capital Investment, International Bancshares, Portola Pharmaceuticals, and Revance Therapeutics New Research Emphasizes Economic Growth GlobeNewswire
May-01-18 08:51AM  Options Traders Expect Huge Moves in Portola (PTLA) Stock Zacks
08:30AM  Today's Research Reports on Trending Tickers: Magellan Health and Portola Pharmaceuticals ACCESSWIRE
Apr-30-18 04:30PM  Portola Pharmaceuticals to Announce First Quarter 2018 Financial Results and Host Conference Call on Wednesday, May 9, 2018 GlobeNewswire +5.67%
Apr-25-18 01:06PM  Portola Pharmaceuticals to Present New Interim Phase 2 Data for Cerdulatinib at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting GlobeNewswire
Apr-04-18 08:30AM  Portola Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire
Portola Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics that could advance the fields of thrombosis and other hematologic diseases. The company's two FDA-approved medicines are Andexxa (coagulation factor Xa (recombinant), inactivated-zhzo), an antidote for patients treated with rivaroxaban and apixaban when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding; and Bevyxxa (betrixaban), an oral, once-daily Factor Xa inhibitor for the prevention of VTE in adult patients hospitalized for an acute medical illness. It is also advancing cerdulatinib, a Syk/JAK inhibitor for the treatment of hematologic cancers. In addition, the company is developing PRT2761, a Syk inhibitor candidate for the treatment for allergic conjunctivitis. Portola Pharmaceuticals, Inc. has collaboration agreements with Bristol-Myers Squibb; Pfizer Inc.; Bayer Pharma, AG; Janssen Pharmaceuticals, Inc.; Daiichi Sankyo, Inc.; Dermavant Sciences GmbH; and Ora, Inc. The company was founded in 2003 and is headquartered in South San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
HOMCY CHARLES JDirectorJan 02Option Exercise5.1045,923234,207165,403Jan 04 05:46 PM
HOMCY CHARLES JDirectorDec 19Option Exercise4.1025,782105,706119,480Dec 19 07:07 PM
HOMCY CHARLES JDirectorDec 17Option Exercise4.1064,218263,294176,689Dec 19 07:07 PM
HOMCY CHARLES JDirectorDec 17Sale18.6164,2181,195,002112,471Dec 19 07:07 PM
HOMCY CHARLES JDirectorNov 14Option Exercise4.1093,698384,16293,698Nov 16 05:24 PM
Curnutte John TInterim Co-President & EVP R&DAug 31Option Exercise0.0017,5000110,084Sep 05 06:43 PM
Dier MardiInterim Co-President & CFOAug 31Option Exercise0.0017,5000107,684Sep 05 07:27 PM
Fu TaoEVP, CBOAug 31Option Exercise0.0020,000087,196Sep 05 07:18 PM
BIRD JEFFREY WDirectorAug 23Buy26.6550,3551,341,810449,053Aug 23 07:32 PM
BIRD JEFFREY WDirectorAug 22Buy26.09202,0825,273,006398,698Aug 23 07:32 PM
BIRD JEFFREY WDirectorAug 21Buy25.17137,5633,462,571196,616Aug 23 07:32 PM
Lis WilliamChief Executive OfficerJul 28Option Exercise0.0035,0000222,035Aug 28 06:13 PM
Fu TaoEVP, CBOJul 28Option Exercise0.005,000089,253Aug 28 06:06 PM
Dier MardiInterim Co-President & CFOJul 28Option Exercise0.0017,5000116,271Aug 28 06:03 PM
Curnutte John TInterim Co-President & EVP R&DJul 28Option Exercise0.0017,5000118,255Aug 28 06:00 PM
Lis WilliamChief Executive OfficerJun 06Sale45.215,113231,159222,035Jun 08 06:18 PM
Curnutte John TExecutive Vice PresidentMar 12Option Exercise8.505,04942,9175,049Mar 14 08:17 PM
Fu TaoEVP, CBOMar 12Sale38.471,13543,66318,346Mar 14 08:19 PM